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Aim: The Helping Evaluate Exenatide in overweight patients with diabetes compared with Long-Acting insulin
(HEELA) study was designed to examine whether the glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide,
could improve HbA1c (≤7.4%) with minimal weight gain (≤1 kg) compared with insulin glargine.
Methods: Patients [body mass index (BMI) >27 kg/m2] with elevated cardiovascular risk and type 2 diabetes
inadequately controlled on two or three oral antidiabetes drugs (OADs) were randomized to add-on exenatide 5–10 μg
b.i.d. (n = 118) or insulin glargine o.d. (titrated to target fasting plasma glucose ≤5.6 mmol/l; n = 117) for 26 weeks.
Results: The study population had baseline mean (s.d.) age of 56.5 (9.1) years and BMI of 34.1 (5.3) kg/m2,a n d
58.5% of patients were taking two OADs. Mean baseline HbA1c was 8.65 (0.68)% in the exenatide group and 8.48
(0.66)% in the insulin glargine group. The proportions of patients achieving the composite endpoint of HbA1c
≤7.4% with weight gain ≤1 kg were 53.4% for the exenatide group and 19.8% for the insulin glargine group
(p < 0.001 for exenatide vs. insulin glargine). Exenatide and insulin glargine did not demonstrate a signiﬁcant
difference in HbA1c improvements [least square (LS) mean [s.e.m.]: −1.25 [0.09]% and −1.26 [0.09]% respectively;
p = 0.924], but had divergent effects on body weight (−2.73 [0.31] vs. +2.98 [0.31] kg respectively, p < 0.001) after
26 weeks. There were more treatment-related adverse events with exenatide but a lower incidence of nocturnal
hypoglycaemia, with no differences in overall or severe hypoglycaemia.
Conclusions: Additional treatment with exenatide resulted in signiﬁcantly more overweight and obese patients with
an elevated cardiovascular risk and type 2 diabetes achieving better glycaemic control with minimal weight gain
compared with insulin glargine.
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2 diabetes, weight gain
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Introduction
Clinical management of overweight and obese patients
with type 2 diabetes inadequately controlled despite two
or more oral antidiabetes drugs (OADs) is particularly
Correspondence:
Melanie J. Davies, Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
E-mail:
melanie.davies@uhl-tr.nhs.uk
Re-use of this article is permitted in accordance with the Terms and Conditions set out at http://www3.interscience.
wiley.com/authorresources/onlineopen.html
challenging [1]. This speciﬁc group of patients have a
high risk of cardiovascular disease [2], and the ideal
therapeutic goal is to improve glycaemic control with
weight loss or minimal weight gain [3].
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Use of combination OADs is often followed by insulin
replacement, although these agentsincrease body weight
to varying extents [4–6]. Use of basal insulin analogues,
including both insulin glargine (Lantus) and insulin
detemir (Levemir), in combination with OADs is asso-
ciated with less weight gain than other insulin regi-
mens[7–9].
Exenatide (Byetta) is a synthetic peptide that acts as
an incretin mimetic and has been shown in vitro to bind
to the glucagon-like peptide-1 (GLP-1) receptor [10]. It
shares antidiabetes actions with the naturally occurring
hormone GLP-1, including glucose-dependent enhance-
mentofinsulinsecretion,suppressionofinappropriately
elevated glucagon levels, slowing of gastric emptying
and reduction of food intake [11]. The effects of adding
exenatide or insulin glargine to OAD therapy have been
reported in several trials [12,13], in which exenatide
was associated with a reduction in body weight [12],
whereas insulin analogue therapy was associated with
weight gain. Similar improvements in glycaemic control
were achieved with either agent [13,14].
The Helping Evaluate Exenatide in patients with dia-
betescomparedwithLong-Actinginsulin(HEELA)study
was designed to compare treatment with exenatide vs.
insulin glargine, on the composite primary endpoint of
HbA1c ≤7.4% and weight gain ≤1 kg in a population of
overweight patients with type 2 diabetes who were at
high risk of cardiovascular disease and not adequately
controlled by two or three OADs.
Patients and Methods
Study Population
This multicentre, randomized, open-label, parallel-arm,
comparator study was undertaken in 36 centres in the
UK between June 2006 and April 2008. Patients with
type 2 diabetes [body mass index (BMI) >27 kg/m2] were
eligible for the study if they had inadequate glycaemic
control (HbA1c 7.5–10.0%), despite treatment with
stable doses of two or three OADs (metformin, sulphony-
lurea and thiazolidinedione) for at least 3 months before
randomization. Patients had at least one cardiovascular
risk factor deﬁned as either a previous cardiovascu-
lar event, peripheral vascular disease, or an abnormal
risk factor [low-density lipoprotein (LDL) >3.0 mmol/l,
high-density lipoprotein (HDL) <1.0 mmol/l (men)
or <1.3 mmol/l (women), triglyceride >1.7 mmol/l,
systolic blood pressure (BP) >130 mmHg, diastolic
BP >80 mmHg or increased waist circumference (Euro-
pean: >94 cm, men, >80 cm, women; Asian: >90 cm,
men, >80 cm, women)]. Exclusion criteria included
history of malignancy, Class III or IV heart disease,
uncontrolled hypertension (systolic BP ≥180 mmHg,
diastolic BP ≥105 mmHg), renal transplantation or
dialysis, chronic renal impairment (serum creati-
nine ≥135 μmol/l for males and ≥110 μmol/l for
females) or liver disease (serum alanine aminotrans-
ferase >3 × upper limit of normal).
The study was performed following institutional ethi-
calapprovalandaccordingtotheDeclarationofHelsinki.
All patients provided written informed consent.
Study Design
Patients were randomized (in a 1 : 1 ratio) to exenatide
or insulin glargine as add-on therapy for 26 weeks. Ran-
domization was stratiﬁed according to the number (two
or three) of OADs. All treatments were self-administered
using reusable injection pens with preﬁlled cartridges.
Exenatide was administered at 5 μg b.i.d. for the ﬁrst
4 weeks, then 10 μg b.i.d. for the remainder of the
study. Insulin glargine was initiated at 10 IU/day and
titrated weekly according to a target fasting plasma
glucose level ≤5.6 mmol/l (≤100 mg/dl). For mean self-
monitored fasting plasma glucose levels≥10 mmol/l, the
increasein insulin glargine dosage was8 IU/day; for fast-
ingplasmaglucoselevelsof7.8–9.9 mmol/l,theincrease
in insulin glargine dosage was 6 IU/day and for fasting
plasma glucose levels of 6.7–7.7 or 5.6–6.6 mmol/l, the
increase in insulin glargine dosage was 4 or 2 IU/day
respectively, as detailed previously [15]. Therapies were
administered by subcutaneous injection in the abdomen,
within15 minbeforemorning andeveningmealsforexe-
natideandoncedailyatbedtimeforinsulinglargine.Pre-
vious OADs were continued at the same stable dosages
unless one or more conﬁrmed or suspected hypogly-
caemic event occurred, when the sulphonylurea dose
could be reduced.
All patients attended clinic visits at screening,
baseline and weeks 4, 8, 12, 18 and 26. Medical
history, blood chemistry, haematology and physical
examination, including height, weight, vital signs and
electrocardiogram, were evaluated at screening. HbA1c
concentrations were measured at screening,baseline and
weeks 12 and 26; body weight was measured and safety
assessed at each clinic visit. Laboratory measurements,
including fasting serum lipids (total cholesterol, HDL
cholesterol, triglycerides and LDL cholesterol), fasting
serum glucose and clinical chemistry, were carried out
at baseline and week 26.
All treatment emergent adverse events (TEAEs) were
recorded and coded according to the Medical Dictio-
nary for Regulatory Activities (MedDRA), version 9.0.
Hypoglycaemic episodes were recorded and deﬁned
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as incidents in which a patient experienced a sign or
symptom associated with hypoglycaemia or who had a
blood glucose <3.4 mmol/l (<60 mg/dl) even if it was
not associated with a sign, symptom or treatment. Severe
hypoglycaemia was deﬁned as an episode with symp-
tomsconsistentwithhypoglycaemiainwhichthepatient
required the assistance of a third party and also had an
associated blood glucose level <2.8 mmol/l (50 mg/dl)
and/orpromptrecoveryafteroralcarbohydrate,glucagon
or intravenous glucose, and/or resulted in coma.
Outcomes and Statistical Analysis
The primary efﬁcacy variable was the proportion of
patients with an HbA1c level ≤7.4% and weight gain
≤1 kg, at the end of the study. Although an HbA1c of
7.4% does not reﬂect optimal glycaemic control, this
cut-off was chosen to reﬂect the UK audit standards for
glycaemic control current at the time the study was per-
formed [16]. The weight change of a gain ≤1 kg was a
pragmatic choice that reﬂected the likely variation in
sequential measurements of weight. The sample size of
234 patients was calculated to provide a power of 90%
to detect a difference in the assumed primary response
rate of 51% (exenatide) vs. 27% (insulin glargine), with a
two-sided signiﬁcance level of 5% and a discontinuation
rate of 20%. Because the most frequently used target is
currently HbA1c <7.0% [3,6], and the UK quality and
outcome framework has recently been changed to reﬂect
this, a post hoc analysis was carried out using a compos-
ite endpoint of HbA1c ≤7.0% with weight gain ≤1k gt o
examine changes in relation to recent practice.
All analyses were performed on a modiﬁed intent-
to-treat basis in randomized patients who received at
least one dose of study drug [full analysis set (FAS)].
The primary efﬁcacy analysis was based on a logistic
regression model for the treatment group, with number
of OADs (two or three) as a factor. The last postbaseline
measurement set of both non-missing HbA1c and weight
was used as the endpoint value. Patients with no base-
line weight measurements and/or missing postbaseline
measurements for HbA1c and/or weight were included
as non-responders in the analysis. Categorical secondary
measures were analysed accordingly.
Continuous secondary measures were explored using
a mixed model repeated measurement (MMRM) analy-
sis with independent variables being treatment group,
visit, the interaction between treatment group and visit,
and the corresponding baseline value. For continuous
variables that were only measured twice, an analysis of
covariance (ANCOVA) model was used, with the change
from baseline to endpoint as the dependent variable
and treatment group, corresponding baseline value and
number of OADs administered, as independent vari-
ables. Fisher’s exact tests were used for the treatment
g r o u pc o m p a r i s o no fd i s c o n tinuation and adverse event
percentages.
All analyses were prespeciﬁed and carried out using
SAS version 9.1.3 (SAS Institute Inc., Cary, NC, USA).
Tests of treatment effects were conducted at a two-sided
signiﬁcance level of 5% and all had 95% conﬁdence
intervals (CIs). The difference between treatments was
calculated on the basis of exenatide vs. insulin glargine
or exenatide minus insulin glargine, depending on the
type of analysis.
Results
Patient Demographics and Characteristics at Baseline
There were 118 patients randomized to exenatide
(ﬁgure 1) and 117 patients randomized to insulin
glargine (116 treated). In the exenatide group, 19 (16.1%)
patients discontinued treatment, and in the insulin
glargine group 12 (10.3%) discontinued (p = 0.248).
The proportions of patients taking two (58.5% over-
all) or three (40.6% overall) OADs and with pre-existing
conditions (97.0% overall) at baseline were similar in
both treatment groups (table 1). Most patients were tak-
ing a combination of metformin and sulphonylurea
(42.3%) or metformin, sulphonylurea and thiazolidine-
dione (40.6%). The majority of patientsin eachtreatment
groupweretakingasulphonylurea (exenatide84.7% and
insulin glargine 86.2%). Hypertension (70.1%) and dys-
lipidaemia (31.6%) were the most common concomitant
conditions reported.
Effect of Exenatide and Insulin Glargine on Glycaemic
Indicators and Weight
The change in weight is plotted against the endpoint
HbA1c in ﬁgure 2. Compared with insulin glargine, exe-
natide was signiﬁcantly more effective in achieving the
primary composite endpoint of HbA1c reduction to
≤7.4% with a weight gain of ≤1 kg [odds ratio (OR):
4.71, 95% CI: 2.62–8.46, p < 0.001; table 2]. The num-
ber of patients achieving this composite endpoint after
26 weeks was 63 (53.4%) in the exenatide group vs. 23
(19.8%) in the insulin glargine group. In each treatment
group, ﬁve patients were analysed as non-responders
because of missing baseline and/or endpoint values for
weight and/or HbA1c. The supportive primary analy-
sis on patients with non-missing values showed similar
results (OR: 4.87, 95% CI: 2.69–8.82, p < 0.001) to those
obtained with the FAS. A post hoc analysis using an
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Fig. 1 Flow diagram of subject disposition.
Table 1 Baseline characteristics of patients receiving exenatide or insulin glargine
Variable Exenatide (n = 118) Insulin glargine (n = 116) Total (N = 234)
Males [n (%)] 83 (70.3) 77 (66.4) 160 (68.4)
Age [mean (s.d.)] (years) 56.8 (10.2) 56.2 (7.9) 56.5 (9.1)
Duration of diabetes [mean (s.d.)] (years) 9.0 (4.6) 8.4 (4.4) 8.7 (4.5)
Weight [mean (s.d.)] (kg) 101.4 (19.8) 97.6 (16.4) 99.5 (18.3)
Body mass index [mean (s.d.)] (kg/m2) 34.6 (5.7) 33.7 (4.9) 34.1 (5.3)
Waist/hip ratio [mean (s.d.)] 0.99 (0.08) 0.98 (0.08) 0.98 (0.08)
HbA1c [mean (s.d.)] (%) 8.65 (0.68) 8.48 (0.66) 8.57 (0.67)
Fasting serum glucose [mean (s.d.)] (mmol/l) 10.84 (2.23) 10.12 (2.22) 10.48 (2.25)
Systolic BP [mean (s.d.)] (mmHg) 134.0 (14.9) 134.5 (17.5) 134.2 (16.2)
Diastolic BP [mean (s.d.)] (mmHg) 79.5 (8.4) 79.8 (9.2) 79.7 (8.8)
Triglycerides [mean (s.d.)] (mmol/l) 1.94 (1.01) 2.31 (2.24) 2.13 (1.75)
Total cholesterol [mean (s.d.)] (mmol/l) 4.45 (1.05) 4.63 (1.20) 4.54 (1.13)
LDL [mean (s.d.)] (mmol/l) 2.38 (0.82) 2.49 (1.02) 2.43 (0.93)
HDL [mean (s.d.)] (mmol/l) 1.14 (0.24) 1.15 (0.29) 1.15 (0.27)
Type of oral diabetes agent∗ [n (%)]
Metformin/sulphonylurea 50 (42.4) 49 (42.2) 99 (42.3)
Metformin/thiazolidinedione 17 (14.4) 15 (12.9) 32 (13.7)
Sulphonylurea/thiazolidinedione 2 (1.7) 4 (3.4) 6 (2.6)
Metformin/sulphonylurea/thiazolidinedione 48 (40.7) 47 (40.5) 95 (40.6)
Pre-existing conditions [n (%)]
Hypertension 85 (72.0) 79 (68.1) 164 (70.1)
Dyslipidaemia 35 (29.7) 39 (33.6) 74 (31.6)
Hypercholesterolaemia 21 (17.8) 19 (16.4) 40 (17.1)
Microvascular complications [n (%)] 31 (26.3) 38 (32.8) 69 (29.5)
Macroangiopathy† [n (%)] 16 (13.6) 21 (18.1) 37 (15.8)
∗Additional two patients only had one OAD at baseline and for analysis were included in the two OADs group.
†Macroangiopathy included angina pectoris, cerebral infarction, cerebrovascular accident, coronary artery disease, intermittent claudication,
myocardial ischaemia, peripheral vascular disorder and transient ischaemic attack.
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Fig. 2 Scatter plot of changes in body weight vs. HbA1c concentration after 26 weeks of exenatide or insulin glargine
treatment in patients with type 2 diabetes; the horizontal line shows a weight gain of 1 kg and the vertical line shows an
HbA1c of 7.4%.
endpoint HbA1c of ≤7.0% with a weight gain of ≤1k g
showed that 46 (39.0%) patients in the exenatide group
and 21 (18.1%) in the insulin glargine group achieved
this composite endpoint (OR: 2.90, 95% CI: 1.59–5.28,
p < 0.001). The median dose of insulin glargine at end-
point was 34.0 (interquartile range: 24.0–52.0) IU/day
and the mean (s.d.) dose was 38.7 (23.5) IU/day.
Changes in HbA1c, weight, waist circumference, fast-
ing blood glucose, lipid proﬁle and BP are summarized
in table 2. Decreases in LS mean values for HbA1c from
baseline after 12 and 26 weeks of either treatment were
statistically signiﬁcant (p < 0.001 for all). The LS mean
difference in the decrease in HbA1c between the exe-
natide and insulin glargine groups was signiﬁcant after
12 weeks (−0.17%, 95% CI: −0.33 to 0.00%; p = 0.044),
but not at 26 weeks (0.01%, 95% CI: −0.24 to +0.27%;
p = 0.924).
Mean body weight decreased with exenatide but
increased following insulin glargine treatment (ﬁgure 3).
The LS mean difference between the changes from
baseline in the two groups was signiﬁcant at 4 weeks
(−1.19 kg, 95% CI: −1.63 to −0.75 kg; p < 0.001) and
all subsequent timepoints: 12 weeks (−3.74 kg, 95%
CI: −4.34 to −3.14 kg, p < 0.001); 26 weeks (−5.71 kg,
95% CI: −6.58 to −4.84 kg, p < 0.001). Waist circumfer-
ence was also statistically signiﬁcantly decreased in the
exenatide group and increased in the insulin glargine
group (table 2), resulting in a signiﬁcant endpoint
difference between treatments (p < 0.001).
The mean [s.d.] decrease from baseline in fasting
serum glucose at endpoint was greater with insulin
glargine (−3.41 [2.85] mmol/l) than with exenatide
(−2.29 [2.64] mmol/l), and the LS mean difference
between the treatments (+1.49, 95% CI: 0.80 to 2.18
mmol/l) was statistically signiﬁcant (p < 0.001). The
proportions of patients who achieved fasting serum glu-
cose ≤5.6 mmol/l were 10.2% with exenatide (n = 12)
and 32.8% with insulin glargine (n = 38). At 26 weeks,
there was a signiﬁcant decrease from baseline in total
cholesterol and triglyceride concentrations in both treat-
ment groups, and for LDL cholesterol with exenatide but
not with insulin glargine (table 2). There was a statisti-
cally signiﬁcant decrease from baseline to endpoint in
systolic BP with exenatide treatment, which was statisti-
cally signiﬁcantly different from the change with insulin
glargine (LS mean difference −3.6 mmHg; p = 0.034),
but no statistically signiﬁcant change in diastolic BP
with exenatide or insulin glargine treatment.
Tolerability
The number of patients with TEAEs (table 3) was 106
(89.8%) in the exenatide and 94 (81.0%) in the insulin
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Table 2 HbA1c, weight, fasting serum glucose, lipid and blood pressure values in patients receiving exenatide or insulin
glargine after 26 weeks of treatment
Between
treatment
Variable Exenatide Insulin glargine p value
HbA1c ≤7.4%, weight gain ≤1k g N N
n( % ) 118 63 (53.4) — 116 23 (19.8) —
[95% conﬁdence interval (CI)] [44.0,62.6] [13.0, 28.3]
Odds ratio [95% CI] 4.71 [2.62, 8.46] <0.001∗
Actual Change from Actual Change from
n measurement n baseline n measurement n baseline
HbA1c (%)
Least square (LS) mean (s.e.m.)∗ 98 7.32 (0.09) 98 −1.25 (0.09) 102 7.31 (0.09) 102 −1.26 (0.09) 0.924†
[95% CI] [7.14,7.50] [−1.43, −1.07]¶ [7.13, 7.49] [−1.44, −1.08]¶
Weight (kg)
LS mean (s.e.m.)∗ 100 97.12 (0.31) 100 −2.73 (0.31) 104 102.83 (0.31) 104 +2.98 (0.31) <0.001†
[95% CI] [96.5,97.7] [−3.34, −2.11]¶ [102.2, 103.4] [2.37, 3.60]¶
Actual Change from Actual Change from
measurement, baseline, measurement, baseline,
n mean (s.d.) n LS mean (s.e.m.) n mean (s.d.) n LS mean (s.e.m.)
Waist circumference (cm) 117 110.2( 1 4 .5) 117 −1.90 (0.52)¶ 114 112.6 (12.8) 114 1.86 (0.53)¶ <0.001‡
Fasting serum glucose (mmol/l) 105 8.51 (2.55) 103 −2.12 (0.25)¶ 104 6.78 (2.67) 101 −3.61 (0.25)¶ <0.001‡
Triglycerides (mmol/l) 108 1.72 (0.92) 105 −0.33 (0.08)¶ 108 1.79 (1.03) 108 −0.38 (0.08)¶ 0.650‡
Total cholesterol (mmol/l) 108 4.09 (0.95) 105 −0.36 (0.07)¶ 108 4.36 (0.97) 108 −0.21 (0.07)§ 0.125‡
LDL (mmol/l) 104 2.15 (0.77) 95 −0.25 (0.06)¶ 105 2.35 (0.84) 101 −0.07 (0.05) 0.017‡
HDL (mmol/l) 106 1.15 (0.27) 101 0.01 (0.01) 106 1.17 (0.28) 106 0.02 (0.01) 0.471‡
Systolic blood pressure (BP) (mmHg) 117 131.5( 1 5 .2) 117 −2.9 (1.2)∗∗ 114 135.5 (17.2) 114 0.7 (1.2) 0.034‡
Diastolic BP (mmHg) 117 79.3( 8 .9) 117 −0.5 (0.7) 114 80.8 (8.7) 114 0.9 (0.7) 0.158‡
The n values show the number of patients with evaluable data for each variable examined.
∗From logistic regression analysis.
†From mixed model repeated measurement analysis.
‡From analysis of covariance.
¶p < 0.001 for within-group change from baseline.
§p = 0.004 for within-group change from baseline.
∗∗p = 0.015 for within-group change from baseline.
glargine groups (p = 0.065). The number of patients with
a TEAE considered possibly drug-related was statisti-
callysigniﬁcantlygreaterwithexenatide (n = 91, 77.1%)
than with insulin glargine (n = 12, 10.3%; p < 0.001).
Gastrointestinal events occurred more commonly in
patients receiving exenatide (70.3%) than those receiv-
ing insulin glargine (21.6%), with nausea being the most
common (48.3% in patients receiving exenatide com-
pared with 2.6% in patients receiving insulin glargine).
Seven patients in the exenatide group discontinued
treatment because of adverse events of nausea (two
patients), vomiting (two patients) and diarrhoea, acute
renal failure and rash (one patient for each) and four
patients discontinued in the insulin glargine group
because of adverse events of injection site pain, asthma,
dyspnoea and rash (one patient for each). A higher inci-
dence of nervous system disorders with exenatide was
seen, although this was largely attributable to a higher
incidence of dysgeusia (8.5% of the exenatide group vs.
0% of the insulin glargine group).
The numbers of patients who discontinued due to
adverse events were not statistically signiﬁcantly dif-
ferent between the two treatment groups (p = 0.539).
Five patients in each group reported at least one serious
adverse event (table 3).
Hypoglycaemia
There was no signiﬁcant difference between exe-
natide and insulin glargine in overall incidence of
symptomatic hypoglycaemic episodes (p = 0.139) and
hypoglycaemic episodes conﬁrmed by blood glucose
measurements <3.4 mmol/l (p = 0.369) (table 3). How-
ever, the incidence of nocturnal hypoglycaemic episodes
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Fig. 3 Changes in body weight of patients with type 2 diabetes during treatment with either exenatide or insulin glargine;
values for each group are least square means with 95% conﬁdence intervals from mixed model repeated measurement
analysis. ∗p < 0.001 exenatide vs. insulin glargine at the same time point.
was signiﬁcantly lower in the exenatide group than in
the insulin glargine group (p = 0.001).
Discussion
In the HEELA study, the proportion of patients with
a ﬁnal HbA1c ≤7.4% and weight gain ≤1 kg was sig-
niﬁcantly higher in the exenatide than in the insulin
glargine group. This conclusion was supported by a
post hoc analysis showing that a signiﬁcantly higher
proportion of the exenatide group than the insulin
glargine group achieved a composite endpoint of HbA1c
≤7.0% and weight gain ≤1 kg. A limitation of the
present study was the open-label nature, which was
necessary because of the different regimens of the
study treatments; a double-dummy design would have
enabled blinding but would have required a much
larger number of injections for each patient. Signiﬁcant
reductions from baseline in HbA1c in these high-risk
patients with type 2 diabetes, inadequately controlled
with two or more OADs, were similar in both treat-
ment groups, but patients with exenatide treatment
had a signiﬁcantly greater decrease in weight compared
with those treated with insulin glargine, where there
were increases in weight, over 26 weeks. Although the
number of patients with a TEAE considered possibly
drug-related was greater with exenatide, there was no
statistically signiﬁcant difference in TEAEs overall or
withdrawals because of adverse events between exe-
natide and insulin glargine. The overall incidence of
hypoglycaemic episodes, including severe episodes,
was not signiﬁcantly different between the two groups,
although it should be noted that the majority of patients
in each group were receiving sulphonylureas. The
incidence of nocturnal hypoglycaemic episodes was
signiﬁcantly less in the exenatide group.
The overweight and obese patients failing on two or
three OADs in the present study were representative of
a problematic group encountered in clinical practice.
For such patients whose HbA1c levels remain above
the target value, despite treatment with OADs, deci-
sions on the next step of additional glucose-lowering
therapy often represents a dilemma [17]. Where two
OADs are administered, the addition of a third agent,
such as a thiazolidinedione, is an option. However, such
treatment results in weight gain and may be associated
withundesirableside-effectsof oedema,congestiveheart
failure and, for women, increased fracture risk [4,18].
Therefore, basal insulin is often implemented as add-on
therapy [15,19], and the efﬁcacy of insulin glargine was
conﬁrmed in the present study in a patient population
with long duration of disease, who were overweight and
had suboptimal glycaemic control despite combination
OADs.
Obesity is an independent risk factor for cardio-
vascular disease and mortality in patients with type
2 diabetes [20]. In the present study, treatment with
exenatide resulted in weight reduction. Other head-to-
head studies of exenatide vs. insulin regimens showed
similar signiﬁcant weight differences in favour of
exenatide [13,21]. In addition, in the present study,
there were reductions with exenatide in waist circum-
ference, triglycerides, total cholesterol, LDL cholesterol
and systolic BP, with no effect on diastolic BP.
Reductions in HbA1c levels and weight changes
in patients treated with exenatide or insulin glargine
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Table 3 Treatment emergent adverse events (TEAEs) by MedDRA system organ class (SOC) and preferred term and incidence
of hypoglycaemic episodes during exenatide and insulin glargine treatment for 26 weeks
Exenatide (n = 118) Insulin glargine (n = 116) Total (N = 234)
[n (%)] [n (%)] [n (%)]
Patients with at least 1 TEAE 106 (89.8) 94 (81.0) 200 (85.5)
MedDRA SOC
Preferred term∗
Gastrointestinal disorders 83 (70.3) 25 (21.6) 108 (46.2)
Nausea 57 (48.3) 3 (2.6) 60 (25.6)
Diarrhoea 22 (18.6) 14 (12.1) 36 (15.4)
Infections and infestations 43 (36.4) 55 (47.4) 98 (41.9)
Nasopharyngitis 24 (20.3) 23 (19.8) 47 (20.1)
Nervous system disorders 36 (30.5) 23 (19.8) 59 (25.2)
Headache 17 (14.4) 18 (15.5) 35 (15.0)
Patients with at least one SAE 5 (4.2) 5 (4.3) 10 (4.3)
Patients with at least one SAE possibly related to study drug 1 (0.8) 0 (0.0) 1 (0.4)
Acute myocardial infarction 1 (0.8) 0 (0.0) 1 (0.4)
Supraventricular tachycardia 1 (0.8) 0 (0.0) 1 (0.4)
Discontinued because of TEAE 7 (5.9) 4 (3.4) 11 (4.7)
Hypoglycaemia incidence†
All episodes
n (%) 59 (50.0) 68 (59.6) 127 (54.7)
[95% conﬁdence interval (CI)] [40.7, 59.3] [50.1, 68.7] [48.1, 61.3]
Odds ratio (OR) [95% CI] 0.68, 95% CI: 0.40–1.14, p = 0.139
Episodes conﬁrmed by blood glucose <3.4 mmol/l
n (%) 37 (31.4) 42 (36.8) 79 (34.1)
[95% CI] [23.1, 40.5] [28.0, 46.4] [28.0, 40.5]
OR [95% CI] 0.78, 95% CI: 0.45–1.35, p = 0.369
Nocturnal hypoglycaemia
n (%) 14 (11.9) 34 (29.8) 48 (20.7)
[95% CI] [6.6, 19.1] [21.6, 39.1] [15.7, 26.5]
OR [95% CI] 0.32, 95% CI: 0.16–0.63, p = 0.001
Severe hypoglycaemia
n (%) 5 (4.2) 6 (5.3) 11 (4.7)
[95% CI] [1.4, 9.6] [2.0, 11.1] [2.4, 8.3]
OR [95% CI] 0.80, 95% CI: 0.24–2.71, p = 0.716
∗Events that occurred in >10% in either treatment group.
†Conﬁdence intervals are based on the exact method, p values are from logistic regression analysis.
in the present study were similar to those observed
in a crossover trial over 16 weeks [12] and in the
Heine et al. [13] open-label study over 26 weeks.
Reservations have been expressed with regard to the
latter study because the ﬁnal mean dose of insulin
glargine (25 IU/day) was relatively low, even though
it was titrated to maintain fasting plasma glucose
<5.6 mmol/l. The lower dose in that study [13] may be
partly explained by lower baseline HbA1c and BMI than
for patients in the present study where the ﬁnal mean
insulin glargine dose (38.7 IU/day) was comparable with
other studies [18,22]. In the present study, the interquar-
tile range for insulin glargine dose at endpoint was
24–52 IU/day,indicatingthatatleast25%ofthepatients
were receiving more than 50 IU/day. Thus, in our study,
more robust comparative data on the use of exenatide or
insulin glargine has been provided. Although the mean
fasting glucose achieved with insulin glargine in the
present study was 6.78 mmol/l, and only 32.6% of the
patients achieved the target of ≤5.6 mmol/l, the study
was only 26 weeks, which may have been insufﬁcient to
fully control fasting glucose in those patients who had
high baseline values.
The importance of glucose control in reducing the
complications of type 2 diabetes is well established.
However, in two recentlarge studies of high-risk patients
with type 2 diabetes, ADVANCE (Action in Diabetes
and Vascular Disease: Preterax and Diamicron Modi-
ﬁed Release Controlled Evaluation) [23] and ACCORD
(Action to Control Cardiovascular Risk in Diabetes) [24],
intensive treatment to achieve near-normal HbA1c lev-
els (6%) did not signiﬁcantly reduce cardiovascular
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events compared with standard targets (7.0–7.9%). In
the ACCORD trial, rapid and aggressive control of glu-
cose was associated with signiﬁcantly increased risk of
death from cardiovascular disease, although this ﬁnd-
ing was not supported by the ADVANCE study. The
factors that may have inﬂuenced these different out-
comes [25] are relevant in terms of the outcomes of the
present study. In the ADVANCE trial, there was lit-
tle change in body weight, whereas in the ACCORD
trial a subgroup of patients gained substantial weight,
with 28% gaining more than 10 kg and 27% of patients
reported severe hypoglycaemia. In the present study,
exenatide improved HbA1c levels but did not result
in increase in weight and the frequency of nocturnal
hypoglycaemia was reduced. Thus, exenatide may have
a role in treating individuals at high risk of cardiovas-
cular disease although long-term outcome studies are
required.
The increased occurrence of gastrointestinal adverse
events, such as nausea and diarrhoea, with exenatide
compared with insulin glargine may limit its use. How-
ever, it is reassuring that, although gastrointestinal side-
effects are common, few patients discontinued as a result
of such side-effects.
In conclusion, the present study provides useful data
on alternative therapies for patients with type 2 dia-
betes and high risk of cardiovascular disease that are
often encountered in clinical practice. Further stud-
ies are required to assess the potential of these dif-
ferent agents in the longer-term treatment of type 2
diabetes.
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